Table 8.
Current status of different schistosomal vaccines in the clinical trials.
| Vaccine Candidate | Species Targeted | Target Antigen | Clinical Trial Phase | References |
|---|---|---|---|---|
| r Sm-14/GLA-SE (r = recombinant) |
S. mansoni | Glutathione S-transferase (GST) from S. mansoni | Phases I and IIa are complete. Phase IIb started. | [156] |
| rSh28GST/Alhydrogel® (Bilharvax) | S. haematobium | Glutathione S-transferase (GST) from S. haematobium | Phases I, II, and III ended. | [159] |
| r Sm-p80/GLA-SE | S. mansoni | Sm-p80 antigen (large subunit of calpain) |
Phase I started. Evaluation for safety and immunogenicity. |
[156] |
| rSm-TSP-2/Alhydrogel® | S. mansoni | Sm-TSP-2 antigen | Phase Ia finished. Phase Ib started. Safety and efficacy in human subjects are evaluated. |
[162] |
| Multi-epitope peptide-based vaccine | S. mansoni | Transmembrane proteins of S. mansoni | Preclinical. | [173] |